Vanda Pharmaceuticals Inc. (FRA:VM4)
4.540
+0.080 (1.79%)
At close: Dec 5, 2025
Vanda Pharmaceuticals Revenue
Vanda Pharmaceuticals had revenue of $56.26M USD in the quarter ending September 30, 2025, with 18.06% growth. This brings the company's revenue in the last twelve months to $212.07M, up 11.12% year-over-year. In the year 2024, Vanda Pharmaceuticals had annual revenue of $198.77M with 3.18% growth.
Revenue (ttm)
$212.07M
Revenue Growth
+11.12%
P/S Ratio
1.51
Revenue / Employee
$576.29K
Employees
368
Market Cap
273.81M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 198.77M | 6.13M | 3.18% |
| Dec 31, 2023 | 192.64M | -61.74M | -24.27% |
| Dec 31, 2022 | 254.38M | -14.30M | -5.32% |
| Dec 31, 2021 | 268.68M | 20.51M | 8.27% |
| Dec 31, 2020 | 248.17M | 20.98M | 9.23% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SAP SE | 36.49B |
| Siemens Aktiengesellschaft | 78.91B |
| Allianz SE | 105.02B |
| Deutsche Telekom AG | 121.02B |
| Siemens Energy AG | 39.08B |
| Rheinmetall AG | 11.00B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Deutsche Bank Aktiengesellschaft | 29.86B |
Vanda Pharmaceuticals News
- 4 days ago - Vanda Pharma Extends FDA Re Review Timeline For Tradipitant Clinical Hold To December 5 - Nasdaq
- 5 days ago - Should You Invest in This Under-the-Radar Weight Loss Stock? - The Motley Fool
- 7 days ago - FDA Extends Review of Vanda Pharmaceuticals' (VNDA) Tradipitant - GuruFocus
- 7 days ago - FDA Fast-Tracks Vanda's Motion Sickness Drug Review After Leadership Shake-Up - Benzinga
- 7 days ago - Vanda Pharmaceuticals Announces Updated FDA Timeline For Tradipitant - Nasdaq
- 7 days ago - Vanda Pharmaceuticals (VNDA) Updates on Tradipitant for Motion Sickness - GuruFocus
- 7 days ago - Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness - PRNewsWire
- 15 days ago - Vanda Pharmaceuticals: Commercial Execution Meets Pipeline Optionality - Seeking Alpha